01Clinical context
What is the rationale?
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
Individualised IV Infusion · IV Supportive Treatments · Istanbul
Individualised IV Infusion · IV Supportive Treatments · Istanbul
Individualised IV Infusion
‘Individualised’ does not mean unrestricted mixing, a proprietary formula or guaranteed benefit. A named care method, ingredient or infusion is not a diagnosis and does not establish personal suitability.
Online information cannot diagnose, select an IV product, formula, dose, rate or laboratory protocol, or promise an outcome. Final decisions require an in-person medical assessment.
Clinical Orientation
Finding · identity · evidence · safety
Four questions precede a personal plan.
The sequence prevents a category name from becoming an automatic treatment recommendation.
02Identity
What exactly is proposed?
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
03Evidence
What does the evidence support?
Evidence must match each product, route, indication and endpoint rather than the label ‘personalised’.
04Safety
When should it stop?
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
What is an Individualised IV Infusion?
Indication · Route of administration · Individual ingredient
Individualised means selecting deliberately — not combining as much as possible.
An individualised IV infusion means the targeted selection of one intravenous active ingredient or a limited combination for a specific medical task. It is created only after need, the oral route, personal risk, product and a measurable endpoint have been assessed.
What an Individualised IV Infusion can do
- Translate a confirmed provision or treatment question into a traceable IV plan
- Deliberately exclude unsuitable ingredients, doses or combinations
- Document each active ingredient with product, batch, individual dose and purpose
- Assess tolerance and the clinical endpoint separately before repetition
What an Individualised IV Infusion cannot do
- Define non-specific fatigue as a deficiency or infusion need without investigating its cause
- Equate a long ingredient list with better personalisation or greater benefit
- Automatically replace oral provision, nutrition or treatment of an underlying condition
- Guarantee energy, immunity, detoxification, anti-ageing or a particular outcome
Personalisation changes the decision pathway, not the scientific requirements. Indication, dose, evidence, contraindications and quality requirements must still be demonstrated separately for every selected active ingredient.
Medical Suitability
Rationale and organ context before venous access
Five checks come before selection.
History, examination, current treatment, contraindications and a proportionate alternative are reviewed together.
- 01
Clarify the problem
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
- 02
Review current treatment
Medicines, allergies, previous procedures or infusions and relevant reactions are considered.
- 03
Identify the exact option
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
- 04
Compare alternatives
No infusion, oral treatment where appropriate, single-product treatment for a defined indication or diagnosis-led care
- 05
Plan follow-up
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
Infusion Safety Path
Before · during · after
Safety depends on a complete, documented chain.
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
01Before
Confirm rationale and product identity
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
- Review history and examination
- Check contraindications
- Keep alternatives open
02During
Control preparation and administration
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
- Maintain traceability
- Monitor tolerance
- Stop when safety changes
03After
Separate expected response from harm
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
- Record observations
- Explain warning signs
- Provide a review route
No public mixture formula, dose, dilution, rate, volume, laboratory panel or infusion schedule is provided.
Evidence and Limits
Method-, product- and indication-specific
Biology or popularity is not proof of clinical benefit.
Evidence must match each product, route, indication and endpoint rather than the label ‘personalised’.
Keep the indication exact
Evidence in one diagnosis or deficiency does not establish a general effect.
Keep the intervention exact
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
Keep endpoints separate
Symptoms, photographs, laboratory values and patient-reported outcomes are not interchangeable.
Retain uncertainty
No remote mixture, prescription, dose, laboratory panel or infusion programme is created.
Manufacturer information may identify a product and instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
As little as necessary, as clear as possible
One need, one formula, one review.
The plan starts small and continues only while the indication, safety and reviewable benefit fit together.
Confirm the need
Document the clinical question, baseline finding and alternative.
Limit the formula
Include only justified active ingredients and individual doses.
Review two levels
Separate early tolerance from the later endpoint.
Decide again
Adjust, change to the oral route or stop the infusion.
Course and Follow-Up
Expected response · complication · reassessment
Repetition is never automatic.
Tolerance and the agreed clinical endpoint are reviewed separately before any further intervention.
- 01Before
Baseline
Record the starting clinical context and intended endpoint.
- 02Same day
Immediate review
Observe tolerance and unexpected reactions.
- 03Later
Clinical review
Compare the relevant finding without automatic attribution.
- 04Decision
Continue, change or stop
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
Risks and Alternatives
Risks of every substance and the venous route
Individually composed does not automatically mean safer.
Possible harms include dosing errors, incompatibility, incorrect concentration, contamination, infection, allergy, venous complications and circulatory or organ burden.
01Person
Organ function
Kidney, liver, cardiovascular system and fluid status influence selection, dose and rate.
02Mixture
Formula control
Identity, concentration, pH, dilution, compatibility and particles are checked before administration.
03Sterility
Aseptic quality
Product, batch, storage, expiry, clean preparation and single-use materials remain traceable.
04Urgent
Warning signs
Breathing difficulty, chest pain, severe swelling, altered consciousness, fever or collapse need immediate help.
Acute severe symptoms receive immediate local medical care. Complete formula and batch documentation helps investigate the cause, but does not replace emergency assessment.
Istanbul and Follow-Up
Assessment and review must travel together
International care needs a workable safety route.
Travel does not shorten observation or remove the need for local medical access.
01
Organise the question
History and existing records prepare discussion without confirming treatment.
02
Assess in person
Personalisation is limited to clinical rationale, contraindications, interactions, organ function, venous access and monitoring decisions.
03
Keep exact records
Each product, licence, manufacturer, batch, compatibility, stability, sterility and preparation responsibility must be explicit; adding many ingredients is not automatically more comprehensive.
04
Plan escalation
Stop immediately for breathing difficulty, chest symptoms, swelling, rash, neurological change or a significant infusion-site reaction.
The Doctor Aslan Approach
Medical position
Personal means deciding more precisely, not infusing more.
Dr İsmail Aslan understands an individualised IV infusion as a limited medical decision pathway: assess the need, classify causes and oral options, use only necessary active ingredients of transparent quality, and reassess benefit, risk and route before every repetition.
Diagnosis before ingredient list
Symptoms are not answered pre-emptively with multiple substances.
Assess oral before intravenous
The more invasive route needs a traceable additional purpose.
Less remains reviewable
Every component has a task, dose and its own safety boundary.
Reassessment before a series
Continuing, changing and stopping remain equally valid decisions.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about Individualised IV Infusion; no personal prescription or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What does ‘individualised’ mean for an IV infusion?+
Individualised does not mean combining as many vitamins or minerals as possible. The medical question, findings, relevant laboratory values, nutrition, medicines, organ function and most appropriate route are assessed first. Only necessary active ingredients receive a defined purpose, exact product, individual dose, safety limits and a predefined review point.
02When is intravenous provision more appropriate than oral provision?+
The venous route is considered only when it offers a traceable advantage for the specific medical task, for example because absorption, urgency, required exposure or tolerance supports it. If the need can be met safely and effectively by an oral or enteral route, that avoids venous access and its additional risks. The decision follows the finding, not a wish for a stronger application.
03Why must the full formula be documented?+
Each active ingredient may have its own contraindications, interactions, dose limits and reactions. Product, manufacturer or source, batch, concentration, individual dose, dilution, compatibility, rate and time are therefore recorded traceably. These details support safe repeat decisions and are important if symptoms arise during or after infusion.
04Why is no fixed infusion series set in advance?+
Need, laboratory findings, medicines, conditions and routes of provision can change. A well-tolerated infusion also does not prove clinical benefit. Before every repeat, the indication, agreed endpoint, adverse effects, formula and oral alternative are reassessed. Without an ongoing medical rationale, treatment is adjusted, stopped or moved to another route.
Next Step
Define the question · verify the option · compare alternatives